OpenClinica Announces Mobile Participant Solution
Participate sets a new standard for usability, integration, and cost effectiveness for electronic patient reported outcomes (ePRO).
OpenClinica announced Participate, a mobile, device-independent solution for engaging participants in clinical research. Participate broadens possibilities for clinical research, by making it easier to meaningfully engage patients and collect high quality, timely data from patients in a way that is convenient for them.
To date, OpenClinica has been known for its clinical trial electronic data capture software. The addition of Participate adds a friendly and effective way to engage patients directly in those same OpenClinica-powered clinical studies. Using Participate with OpenClinica EDC allows researchers to design participant-facing events, reminders, and assessments alongside clinical visits and CRFs, using OpenClinica's existing study build tools. All the clinical and patient reported outcomes data are captured in a single place. As data are submitted by study participants, their activities become part of the same regulatory compliant audit trail that tracks all clinical user activity. The data participants submit, are immediately available for review and analysis alongside CRF data from other sources.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
